• image

    the Phase 3 trial DIAGNODE-3

    and other ongoing trials

  • image

    Developing precision therapies

    for type 1 diabetes

  • image

    Intralymphatic immunotherapy

    with Diamyd®

Notification of attendance at Extra General Meeting

The shareholders of Diamyd Medical AB (publ) are summoned to an Extra General Meeting at 10:00 a.m. on Tuesday, October 10, 2023.



 Dates for financial information and other events
Data pager
Data pager
October 2 − October 6, 2023
EASD 2023
October 9, 2023
Aktiedagen i Lund
October 10, 2023
Extra General Meeting
October 11, 2023
Year-end report
Year-end report 2022/2023
October 18 − October 21, 2023
ISPAD 2023
October 25 − October 26, 2023
BioStock Life Science Summit 2023

I am very happy to announce that all eight European countries where DIAGNODE-3 is ongoing have randomized patients to the trial and we hope to start the trial in the US shortly.

image Ulf Hannelius
President and CEO, Diamyd Medical AB
CEO Comments, Quarterly Report 3 22/23
A new facility for manufacturing of biological products is being set up in Umeå, the Capital of Västerbotten County in Sweden. The primary purpose is the manufacture of recombinant GAD65, the active pharmaceutical ingredient in the investigational medicine Diamyd®, an antigen-specific immunotherapy currently in late-stage clinical development.

Diamyd Medical has chosen Cytiva’s FlexFactory, a configurable single-use bioprocess platform for the manufacturing process that is based on a baculovirus-insect cell expression system.


Diamyd Medical develops therapies for type 1 diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)

Read More

Order GAD for preclinical research